Journals / Viral Hepatitis Journal / 2021 / Cilt: 27 - Sayı: 1

Genotype Distributions and Hepatitis B Coinfection in Hepatitis C Patients at a University Hospital

Bir Üniversite Hastanesinde Hepatit C ile Enfekte Hastalarda Genotip Dağılımları ve Hepatit B Koenfeksiyonu

Pages
13–18
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

HBV exposure was in 27.7%, isolated anti HBc IgG positivity was in 4.4%, and 21% were naturally immune to HBV.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease.
📊
Key Findings & Data:Our study aimed to determine HBV coinfection rates in HCV patients.
💡
Conclusion & Impact:HBV exposure was in 27.7%, isolated anti HBc IgG positivity was in 4.4%, and 21% were naturally immune to HBV.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. Comorbidity with the hepatitis B virus (HBV) leads to progressive fibrosis and severe liver disease. Our study aimed to determine HBV coinfection rates in HCV patients. Materials and Methods: This single-center study retrospectively examined anti-HCV-positive patients monitored at our center in January 2015-June 2020. The patients’ hepatitis B surface antigen, anti-hepatitis B core antigen immünoglobulin (anti-HBc IgG), anti- HBs, anti-delta, anti-human immunodeficiency virus (HIV), HCV- RNA, HBV-DNA and HDV-RNA test results were analyzed. Results: Among 602 anti-HCV-positive patients, 462 (76.7%) with positive HCV-RNA values were included. The median age was 55.27 (18-88), while 279 (60.4%) were female. The most prevalent genotype was 1b 60.7%. HCV/HBV coinfection was found as 1.8%. HBV exposure was in 27.7%, isolated anti HBc IgG positivity was in 4.4%, and 21% were naturally immune to HBV. HBV-DNA was

Özet

Amaç: Hepatit C virüsü (HCV) enfeksiyonu kronik karaciğer hastalığının majör nedenidir. Hepatit B virüsü (HBV) ile birlikteliği ilerleyici fibrozis ve ciddi karaciğer hastalığına yol açmaktadır. Çalışmamızda kronik HCV ile enfekte hastalarda HBV koenfeksiyonu oranlarını saptamayı amaçladık. Gereç ve Yöntemler: Bu tek merkezli kohort çalışmasında Ocak 2015-Haziran 2020 tarihleri arasında merkezimizde izlenen anti-HCV pozitif hastalar retrospektif olarak tarandı. Hastaların hepatit B yüzey antijen, anti-hepatit B çekirdek antijen immünoglobulin (anti-HBc IgG), anti-HBs, anti-delta, insan bağışıklık yetmezliği virüsü (anti-HIV), HCV-RNA ve HBV-DNA, HDV-RNA test sonuçları istatistiksel olarak analiz edildi. Bulgular: Anti-HCV pozitif 602 hastanın, HCV-RNA değeri pozitif 462’si (%76,7) çalışmaya dahil edildi. Olguların yaşları medyan 55,27 (18-88), 279’u (%60,4) kadındı. En sık genotip, 1b %60,7 idi. HCV/ HBV koenfeksiyonu %1,8 olarak bulundu. HBV maruziyeti olguların %27,7’sinde, izole anti HBc IgG pozitifliği %4,4’ünde tespit edilirken, %21’i HBV’ye doğal bağışıktı. HBV-DNA hastaların tümünde

🔖

Cite This Article

Aydın, Ö. (2022). Genotype Distributions and Hepatitis B Coinfection in Hepatitis C Patients at a University Hospital. Viral Hepatitis Journal, Cilt: 27 - Sayı: 1, 13–18. https://ajindex.com/articles/646323

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Mavilia MG, Wu GY. HBV/HCV coinfection: Viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018;6:296-305
  2. WHO. Global hepatitis report, 2017. World Health Organization. Geneva, Switzerland; 2017: Avaible from; http//apps.who.int/iris/ bit stream/10665/255016/1/9789241565455 3. Zarębska-Michaluk D, Flisiak R, Flisiak-Jackiewicz M. Management of hepatitis B and hepatitis C coinfection: an expert review. Expert Rev Anti Infect Ther. 2020;18:1033-1044 4. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis. 2008;12:661-674
  3. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512-520
  4. Chen F, Zhang J, Wen B, Luo S, Lin Y, Ou W, Guo F, Tang P, Liu W, Qu X. HBV/HCV dual infection impacts viral load, antibody response, and cytokine expression differently from HBV or HCV single infection. Sci Rep. 2016;6:39409
  5. Europian Association for the study of the liver. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69:461-511
  6. Jiang XW, Ye JZ, Li YT, Li LJ. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018;24:3181-3191
  7. Chen G, Wang C, Chen J, Ji D, Wang Y, Wu V, Karlberg J, Lau G. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta- analysis. Hepatology. 2017;66:13-26
  8. Lee SW, Lee TY, Yang SS, Peng YC, Yeh HZ, Chang CS. Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals. Gastroenterology Res. 2018;11:124-129
  9. Fidan I, Çuhadar T, Koç Z, Karakuş R. Detection of the prevalence of HBV/HCV coinfection in anti HCV positive samples. Klimik J. 2018;31:16-19
  10. Tahmaz A, Alkan Çeviker S, Günal Ö, Kılıç SS. Evaluation of isolated hepatitis B core antibody (anti-HBc IgG) seropositivity in chronic hepatitis C infected patients. KSU Medical Journal. 2019;14:119-123
  11. Akca F, Demir-Akca AS, Aydemir S, Aktunç E. The frequency of hepatitis B virus infection in patients chronically infected with hepatitis C virus: a retrospective study. Türk Aile Hek Derg. 2012;16:3-7
  12. Karaca Ç, Çakaloğlu Y, Demir K, Özdil